Novartis AG (NYSE:NVS) Shares Bought by Delphi Management Inc. MA

Delphi Management Inc. MA raised its stake in Novartis AG (NYSE:NVS) by 8.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,309 shares of the company’s stock after purchasing an additional 1,128 shares during the period. Delphi Management Inc. MA’s holdings in Novartis were worth $1,392,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Centaurus Financial Inc. raised its position in Novartis by 1.7% in the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after purchasing an additional 98 shares in the last quarter. Bryn Mawr Capital Management LLC raised its position in Novartis by 0.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock valued at $1,254,000 after purchasing an additional 100 shares in the last quarter. Rothschild Investment LLC raised its position in Novartis by 0.6% in the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock valued at $1,623,000 after purchasing an additional 101 shares in the last quarter. Meridian Wealth Management LLC raised its position in Novartis by 2.6% in the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company’s stock valued at $405,000 after purchasing an additional 106 shares in the last quarter. Finally, Angeles Wealth Management LLC raised its position in Novartis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company’s stock valued at $316,000 after purchasing an additional 110 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Barclays reissued an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Trading Up 2.9 %

NYSE:NVS opened at $112.24 on Tuesday. The stock’s 50 day moving average price is $105.65 and its 200 day moving average price is $107.54. The company has a market capitalization of $229.41 billion, a PE ratio of 19.09, a P/E/G ratio of 1.70 and a beta of 0.53. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.

Novartis (NYSE:NVS) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, research analysts anticipate that Novartis AG will post 8.45 EPS for the current year.

Novartis Announces Dividend

The company also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s dividend payout ratio is presently 42.69%.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.